Drugs / ATG (rabbit)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00278512 | Aug 2003 → Jun 2016 | vasculitis | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG (rabbit) | “Drug: ATG (rabbit)” NCT00278512 ↗ |
| Known as | ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00278512 ↗ |
| Action | Deplete | “ATG promotes the depletion of T cells from the circulation” NCT00278512 ↗ |
| Modality | Protein / enzyme biologic | “ATG is a gamma globulin preparation obtained from hyperimmune serum of rabbits immunized with human thymocytes.” NCT00278512 ↗ |
| Route | Intravenous | “ATG is administered intravenously at a dose of 0.5 mg/kg recipient body weight on day -6 and a dose of 1.0 mg/kg recipient body weight on days -5, -4, -3, -2 and -1.” NCT00278512 ↗ |